Introduction
Salivary gland tumours are uncommon. The reported incidence is approximately 3% of all head and neck neoplasms 13 . Tumours of minor salivary gland origin account for only 10-15% of all salivary gland neoplasms 10 . The percentage of minor salivary gland tumours is higher in the African series 6, 8 , although one of these papers is from a maxillofacial unit 6 , which may see minor salivary gland tumour more than major salivary gland tumour. Most studies include major and minor salivary gland tumours together and there are few articles that study minor salivary gland tumours separately. The papers that have reported minor and major salivary gland tumours separately were done so from outside of the USA.
The purpose of this study is to report our experience with minor salivary gland tumours at the University of Maryland at Baltimore (UMAB), Department of Oral and Maxillofacial Surgery.
Materials and methods
The records of all patients with minor salivary gland tumours treated in the Department of Oral and Maxillofacial Surgery, UMAB during March 1991 to February 2001 were reviewed. A total of 80 patients with intraoral minor salivary gland tumours were identified.
Criteria for inclusion were biopsyproven minor salivary gland tumours that occurred in the oral cavity. Most patients with intraoral minor salivary gland tumours received initially incisional biopsy from the private oral and maxillofacial surgeons. All patients had incisional biopsy performed before receiving the definitive treatment.
All patients were investigated in a retrospective manner by an extensive chart review. Age, sex, symptoms, duration of symptoms, location, race, histology, and modalities of treatment were examined and compared to those in the existing literature.
Results
A total of 80 minor salivary gland tumours were identified in 49 female patients and 31 male patients. The female to male ratio was 1.6:1, with a female to male ratio of 1.9:1 with the malignant tumours and 1:1.1 with the benign tumours.
The patients range in age from 9-84 years with malignant and 33-90 years with benign tumours. The median age of males and females with benign minor salivary gland tumours was 64.5 and 58, respectively. For the malignant neoplasms, the median age for males and females was 52 and 54, respectively. The median age for males and females with minor salivary gland tumour was approximately the same: 54 and 55, respectively. The median age for those with malignant minor salivary gland tumours was 6 years younger than for those with benign tumours (54 years for malignant and 60 years for benign). By histological type, the median age for those with mucoepidermoid carcinoma was younger than for those with other histological types (48.5 years for mucoepidermoid carcinoma, 58 years for pleomorphic adenoma, 63 years for adenoid cystic carcinoma and 56 years for polymorphous low-grade adenocarcinoma). Six of the malignant tumours (6 out of 61) (10%) occurred in children aged 9-16 years and four of these were mucoepidermoid carcinomas; all of the benign tumours occurred in adults.
Race was reported in 77 out of 80 patients-71.3% were Caucasian and 22.5% were black. The distribution of minor salivary gland tumours by race indicated that the majority of patients who had pleomorphic adenoma, mucoepidermoid carcinoma, and polymorphous low-grade adenocarcinoma were Caucasian, while there was an equal Caucasian to black predilection with adenoid cystic carcinoma ( Table 1) .
The most common complaint that brought patients to see either the dentist or oral and maxillofacial surgeon was a painless swelling in the mouth (61.25%). Of these patients, 20% were without symptoms and the tumour was found on routine dental examination. The majority of patients with benign minor salivary gland tumours (68.4%) had symptoms for more than 1 year before seeking treatment (Fig. 1 ). Of patients with malignant minor salivary gland tumours, 50.8% had symptoms less than 1 year before receiving treatment. Of the patients with malignant tumours, 27.9% had experienced symptoms for longer than 1 year and 13.1% experienced no symptoms (found on routine dental examination), respectively (Fig. 2) .
The majority of the patients with minor salivary gland tumours who received treatment at UMAB presented with malignant minor salivary gland tumours. Of these (76.3%) (61 out of 80) were classified as malignant and (23.7%) (19 out of 80) were classified as benign.
The commonest sites for minor salivary gland tumours were the palate, buccal mucosa and upper lip, which accounted for 77.5% of cases. The palate was the most common site for all minor salivary gland tumours (53.8%) and (60.5%) (26 out of 43) of palatal tumours were malignant. The buccal mucosa was the second most common site for malignant salivary gland tumours ( Table 2) .
The most common sites for malignant minor salivary gland tumours were the palate, buccal mucosa, maxilla, and retromolar fossa at 42.6%, 21.3%, 8.2%, and 8.2%, respectively.
There were 19 patients who had benign minor salivary gland tumours of which two (10.5%) were recurrent tumours that were initially treated elsewhere. Pleomorphic adenoma was the most common minor salivary gland tumour (17 out of 19 cases, 89.5% of benign minor salivary gland tumour) and accounting 21.3% of all minor salivary gland tumours. The palate was the most commonly involved site of pleomorphic adenoma (88.2%, 15 out of 17 cases of pleomorphic adenoma). The other site of presentation for pleomorphic adenoma was the upper lip. There was one patient who had basal cell adenoma of the palate and one with canalicular adenoma of the upper lip.
Mucoepidermoid carcinoma was the most common malignant lesion noted in this study. There were 33 tumours diagnosed as mucoepidermoid carcinoma, Polymorphous low-grade adenocarcinoma was the second most common malignancy. The incidence of polymorphous low-grade adenocarcinoma was 14.8% (9 out of 61 cases) of the malignant minor salivary gland tumours and 11.3% (9 out of 80 cases) of all tumours. The buccal mucosa and palate were the most common sites for polymorphous low-grade adenocarcinoma and the remaining locations were the upper lip and maxilla.
Adenoid cystic carcinoma was the third most common site of malignant minor salivary gland tumours. There were seven patients who had adenoid cystic carcinoma, accounting for 11.5% of malignancies and 8.8% of all minor salivary gland tumours. The palate was the most common site. The other sites where adenoid cystic carcinoma presented were the maxilla and upper lip.
All benign minor salivary gland tumours were treated surgically by wide local excision, except for two patients who did not receive any treatment due to their advanced age and poor general health. The commonest treatment modality for malignant minor salivary gland tumours (70.8%) was surgery alone. Surgery consisted of wide local excision and composite resection with or without neck dissection. The other treatment modalities for malignant salivary gland tumours were combined treatment (Table 3 ). There were five patients who either received treatment at other institutions or refused treatment.
There were no recurrences in benign minor salivary gland tumours with a follow-up from 3 months to 5 years. There were 61 patients with malignant tumours, of which 48 had low-or intermediate-grade
cancers. These included low-and intermediate-grade mucoepidermoid carcinoma, polymorphous low-grade adenocarcinoma, clear cell carcinoma, low-grade adenocarcinoma, basal cell adenocarcinoma, mucous-producing cyst adenocarcinoma and acinic cell carcinoma. Three patients were lost to follow-up; of the remaining 45 patients, 42 remain cancer-free (93.3%) with a variable follow-up ranging from 3 months to 9 years. One woman with persistent intermediategrade mucoepidermoid carcinoma, which recurred following four surgeries, radiation therapy and injections with p53 adenovirus, died of other causes. Two patients remain alive with persistent disease. One male patient had a massive, neglected low-grade adenocarcinoma with persistent tumour at the skull base. One woman had polymorphous low-grade adenocarcinoma that recurred locally and in the neck. Following neck dissection and maxillectomy, the tumour again recurred in the maxilla and retropharyngeal nodes; following further excision, it recurred in the orbit and she has refused further treatment.
There were 13 patients with highgrade tumours, either high-grade mucoepidermoid carcinoma or adenoid cystic carcinoma. Of the seven patients with high-grade mucoepidermoid carcinoma, four (57%) had lymph node metastases at presentation. Two patients (15.3%) died because of disease: one male with adenoid cystic carcinoma with lung, brain, and bone metastases, and one female with high-grade mucoepidermoid carcinoma of locoregional recurrence after surgery plus radiation and further salvage surgery. One patient with adenoid cystic carcinoma died 1-week postoperatively of a presumed pulmonary embolism. One patient with highgrade mucoepidermoid carcinoma is alive with pulmonary metastases unresponsive to chemotherapy. Thus nine out of 13 (69%) of individuals with high-grade malignancies are alive without cancer but the follow up period is short-7 years 6 months is the longest-this is very inadequate for adenoid cystic carcinoma.
Discussion
Most studies including this one have shown that minor salivary gland tumours are more common in females than males, with a ratio range from 1.2:1 to 1.9:1 17, 21 . The age range of the patients was 9-90 years. There was no statistically significant difference in the ages of females and males in the benign and malignant minor salivary gland tumour groups. The present study showed that the median age of the patients with malignant minor salivary gland tumours is 6 years younger than those with benign tumours. This may have been due to the large proportion of mucoepidermoid carcinomas. On the other hand, the study by W et al. revealed that the patients with benign tumours were 5 years younger than those with malignant tumours 21 . However, there was no statistically significant difference in the age of patients with the benign and malignant salivary gland tumours.
There was a Caucasian predilection for minor salivary gland tumours that corresponds to the study by W et al. (71.3% from the present study and 84.3% from W et al.) 21 . However this may be due to our racial population mix as our percentage for oral squamous cell carcinoma is similar.
The percentage of malignant minor salivary gland tumours from most studies was quite similar, representing 34.8% to 65% 11, 16, 17, 20, 21 . However, a high percentage of benign tumours were reported in the study by I & S 12 , which they attribute to an increased proportion of black patients in their study group. They stated that black people are affected by pleomorphic adenoma about 3.5 times more often than Caucasian people.
In this study, the percentage of malignant minor salivary gland tumours was 76.3%, which corresponds well to the studies of S & P 14, 18 . The high percentage of malignant minor salivary gland tumours may result from a 'harvesting effect', with the majority of our referrals from oral and maxillofacial surgeons who treat the benign minor salivary gland tumours and refer the malignant minor salivary gland tumours to our institution.
The frequency of pleomorphic adenoma in this study was 21.3%, which was lower than that found in other studies. The incidence of pleomorphic adenoma has been reported to range from between 40.8-50% up to 70% (Table 4) 4,12 . The incidence of mucoepidermoid carcinoma in this study (41.3%) was higher than in most published studies, accounting for 8.6-33.9% 5, 11, 12, 17, 18, 20, 21 . Mucoepidermoid carcinoma was the most common malignant salivary gland tumour reported in this study, although a number of previous surveys have reported that adenoid cystic carcinoma is the most common malignant minor salivary gland tumour 1, 11, [17] [18] [19] . This difference in the histological distribution may be related to the histological criteria that was used for the diagnosis of adenoid cystic carcinoma. Series prior to 1984 did not recognize polymorphous low-grade adenocarcinoma as an entity and it was frequently diagnosed as adenoid cystic carcinoma. Furthermore, the study by E & C noted that the incidence of mucoepidermoid carcinoma in British and western European studies was considerably lower than that in reports from the USA, which might represent a true geographic variation 11 . The frequency of polymorphous lowgrade adenocarcinoma in the present study was 11.3% of all minor salivary gland neoplasms which was the same range reported in other studies (1.4-15.7%) 3, 12, 20, 21 . However, in some reports polymorphous low-grade adenocarcinoma was not found or reported as a small number. This was probably because there was overlap of histological features between polymorphous lowgrade adenocarcinoma and adenoid cystic carcinoma and some studies were reported before the polymorphous lowgrade adenocarcinoma was first introduced as a distinctive neoplasm in 1984 9, 11 . The anatomical distribution of minor salivary gland tumours found in the present study is slightly different from that in other studies. In this study, the palate, buccal mucosa, and maxilla were the most predominant sites, while in other major surveys the palate, upper lip, and buccal mucosa were the predominant sites. The palate was reported to be the predominant site of occurrence and is the location of occurrence in between 40-55% 4,15,21 of all cases; this has been reported to be as high as 75%. This study reports that 53.8% of all minor salivary gland tumours occurred in the palate and that 60.5% (26 out of 43) were malignant; other studies reported that approximately 50% of all minor salivary gland tumours occurred in the palate and 50% were malignant 2, 7, 11, 21 . It is not possible to differentiate malignant from benign tumours clinically. A total of 27.95 (one in four) malignant tumours were present for more than 1 year and 13.1% (one in seven) were a symptomatic. Therefore all suspected minor salivary gland tumours require biopsy to avoid further delay in diagnosis.
Although two of our 19 patients with benign tumours had recurrent lesions, we encountered no recurrence following adequate local surgery. In our 61 malignant tumours, only five were found to have clinically proven lymph node metastases (8.2%): four high-grade mucoepidermoid carcinomas and one polymorphous low-grade adenocarcinoma. Two patients died of cancer, one of distant metastases and one of locoregional recurrence. One patient died perioperatively; four patients have persistent disease, three with local recurrence (one died of other causes) and one with lung metastases. A total of 54 patients (54 out of 61; 88.5%) remain alive without obvious cancer, although the follow-up period is short. Histological type, grade, stage and site are all important determinants of prognosis and aggressive surgery with wide margins is the best method of treatment.
The information from this report was unique and different from other studies because it came from a maxillofacial oncology unit rather than a pathology unit. 
